PAVmed shareholders approve stock issuance, charter amendment, and equity plan changes

PAVmed will implement a 1-for-30 reverse stock split effective Jan 2, 2026 to comply with Nasdaq's $1.00 minimum bid requirement. At a special meeting representing ~54.1% of outstanding voting power, shareholders approved conversion/issuance related to 60,000 Series D preferred (640,946 for / 72,380 against), an amendment allowing director removal by a majority (858,651 for / 60,825 against), and an increase to the 2014 LTIP by 1,500,000 shares (to 1,713,517) with votes of 756,683 for / 162,305 against. The stock has fallen ~12% over the past week to $8.67 (market cap ~$12.5M); these are governance and compliance actions likely to have modest, company-specific market impact in the near term.

Analysis

Governance tweaks that make director removal easier materially lower the cost and friction for incoming activists or a strategic buyer to remake the board quickly. That makes a near-term governance-driven rerating — either positive (if a credible bidder appears) or negative (if management is forced into opportunistic financing) — more probable than it was previously.

The capital‑structure actions change supply dynamics more than headline optics imply: a cosmetic price adjustment will compress float and can briefly lift the quoted share price, but the real pressure comes when newly authorized/easily convertible equity hits the market to fund operations. If management uses the expanded issuance capacity to avoid a cash crisis, expect heavy share creation over quarters that can swamp any transient pop from the compliance action and amplify volatility given low free‑float depth.

Time and catalyst stacking is straightforward: short-term technical relief from compliance is the dominant near‑term story, while conversion/exercise and LTIP vesting/timing are the multi‑month dilution anchors. Binary upside exists if an activist or buyer steps in now that director removal is easier — that would compress downside and could produce rapid re‑rating — but absent that, downside from supply shock is the path of least resistance.

Key Decisions for Investors

• Short PAVM equity size 3–6 months (suggest 5–10% of a tactical book). Risk-reward: target 30–50% downside; initial stop at +20% from entry. Use hard position limits because liquidity is thin and gap risk is real.
• If liquid, buy PAVM puts 3–6 months to capture dilution and volatility; if options illiquid, implement short stock instead. Position sizing should assume potential rapid squeezes; cap exposure to under 5% NAV for concentrated books.
• Relative-value pair: short PAVM / long SMCI equal notional for 3 months to 6 months to isolate company‑specific dilution risk vs secular tech momentum. Expect a skewed payoff — asymmetric downside in PAVM with SMCI providing carry and upside; close if PAVM announces capital‑raising terms that materially limit dilution.
• Event-driven long (small, <2% NAV) only after concrete cleanup signals: either a binding buyout process or a commensurate reduction in fully diluted share count. Binary payoff: asymmetric upside (2x–4x) on a sale/strategic transaction vs limited downside after dilution clears.